Get the Stockscreener App
3.8355
0.38%
-0.0145
Bionano Genomics Inc stock is traded at $3.8355, with a volume of 22,293.
It is down -0.38% in the last 24 hours and up +24.53% over the past month.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
See More
Previous Close:
$3.85
Open:
$3.87
24h Volume:
22,293
Relative Volume:
0.16
Market Cap:
$12.56M
Revenue:
$36.12M
Net Income/Loss:
$-232.49M
P/E Ratio:
-0.2157
EPS:
-17.78
Net Cash Flow:
$-126.87M
1W Performance:
-5.30%
1M Performance:
+24.53%
6M Performance:
-77.10%
1Y Performance:
-93.49%
1-Day Range:
$3.80
$3.9471
1-Week Range:
$3.6067
$4.1388
52-Week Range:
$2.68
$72.60
Bionano Genomics Inc Stock (BNGO) Company Profile
Name
Bionano Genomics Inc
Sector
Industry
Phone
(858) 888-7600
Address
9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Compare BNGO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNGO
Bionano Genomics Inc
|
3.8355 | 12.56M | 36.12M | -232.49M | -126.87M | -17.78 |
|
ISRG
Intuitive Surgical Inc
|
536.51 | 189.75B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.75 | 48.62B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
167.22 | 48.37B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.04 | 35.18B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.27 | 16.46B | 3.90B | 392.30M | 288.10M | 1.95 |
Bionano Genomics Inc Stock (BNGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-12-22 | Resumed | BTIG Research | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Jun-16-21 | Initiated | BTIG Research | Buy |
| Sep-24-20 | Initiated | Ladenburg Thalmann | Buy |
| Apr-08-20 | Initiated | Oppenheimer | Outperform |
View All
Bionano Genomics Inc Stock (BNGO) Latest News
When (BNGO) Moves Investors should Listen - news.stocktradersdaily.com
Renaissance Technologies LLC Takes Position in Bionano Genomics, Inc. (NASDAQ:BNGO) - Defense World
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025 - The Manila Times
Geode Capital Management LLC Acquires 114,822 Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) - Defense World
Bionano Laboratories (BNGO) Gains Key Recommendations for Optical Genome Mapping | BNGO Stock News - GuruFocus
International Consortium for Optical Genome Mapping - GlobeNewswire
BioNano Genomics Executes Significant Reverse Stock Split - MSN
Where are the Opportunities in (BNGO) - news.stocktradersdaily.com
Bionano Genomics (BNGO) Highlights Optical Genome Mapping in Det - GuruFocus
Bionano Genomics (BNGO) Highlights Optical Genome Mapping in Detecting Genetic Disorders | BNGO Stock News - GuruFocus
Bionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic Disease - The Manila Times
Breakthrough Genetic Testing Study Reveals 98.8% Accuracy Rate for Bionano's Cost-Cutting Technology - Stock Titan
Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results - ADVFN
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 - ADVFN
Brokers Set Expectations for BNGO Q1 Earnings - Defense World
Bionano Genomics (BNGO) Projects Stable Revenue Growth for 2025 - GuruFocus
Bionano Genomics (BNGO) Sees Revenue Upgrade Despite Lower Price Target - GuruFocus
Bionano Genomics (BNGO) Faces Revenue Growth, Missed EPS Targets - GuruFocus
Bionano Genomics (BNGO) Advances Multiple Myeloma Analysis - GuruFocus
Bionano Genomics (BNGO) Reports Q4 2024 Earnings: Revenue Decline but Margin Improvement - GuruFocus
Bionano Genomics (NASDAQ:BNGO) Coverage Initiated at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Bionano Genomics (BMV:BNGO) with Buy Recommendation - Nasdaq
HC Wainwright & Co. Initiates Coverage of Bionano Genomics (LSE:0A4K) with Buy Recommendation - Nasdaq
HC Wainwright & Co. Initiates Coverage of Bionano Genomics (BNGO) with Buy Recommendation - Nasdaq
HC Wainwright Initiates Bionano Genomics With Buy Rating, $10 Price Target - marketscreener.com
Richardson Electronics Q3 2025 Earnings Call Transcript - MarketBeat
Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM - The Manila Times
Breakthrough: French Study Reveals Game-Changing Multiple Myeloma Detection Method - Stock Titan
(BNGO) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive - simplywall.st
Scotiabank Boosts Bionano Genomics (NASDAQ:BNGO) Price Target to $4.00 - Defense World
Bionano Genomics Inc Reports Q4 Revenue of $8.2 Million, Surpassing Estimates - GuruFocus
Analysts Are Upgrading Bionano Genomics, Inc. (NASDAQ:BNGO) After Its Latest Results - Yahoo Finance
Bionano Genomics Q4 Earnings Call: Mixed Sentiments and Strategic Shifts - TipRanks
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2024 Earnings Call Transcript - Insider Monkey
Bionano Genomics Inc (BNGO) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance
Bionano Genomics Inc (BNGO) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and ... By GuruFocus - Investing.com Canada
Bionano Genomics Reports 2024 Financial Results - TipRanks
Bionano Genomics outlines 2025 revenue guidance of $29M-$32M with strategic focus on utilization - MSN
Bionano Genomics (BNGO) Q4 2024 Earnings Call Transcript - Yahoo Finance
Bionano Genomics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Bionano Genomics Q4 2024 sees revenue drop By Investing.com - Investing.com South Africa
Earnings call transcript: Bionano Genomics Q4 2024 sees revenue drop - Investing.com
Bionano Genomics, Inc. SEC 10-K Report - TradingView
Bionano Genomics Reports Q4 and Full-Year 2024 Results - TradingView
Stock Market Correction: 2 Warren Buffett Stocks to Buy Hand Over Fist - The Globe and Mail
Bionano Genomics Inc expected to post a loss of $6.00 a shareEarnings Preview - TradingView
SoFi Stock Is Down 23% YTD. Should You Buy the Dip or Stay Away? - The Globe and Mail
What's Next: Bionano Genomics's Earnings Preview - Benzinga
Q4 Earnings Outperformers: Fastenal (NASDAQ:FAST) And The Rest Of The Maintenance and Repair Distributors Stocks - The Globe and Mail
Hakluyt appoints Ronald Sugar to its International Advisory Board - The Globe and Mail
Bionano Genomics Inc Stock (BNGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.40%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):